Two lanes, both priced in full
The pricing page runs a six-step ladder for tirzepatide and a five-step ladder for semaglutide on the pay-as-you-go lane, then repeats both drugs on the membership lane at flatter, higher rates. Every step carries a figure.
The difference between the lanes is not a discount. On pay-as-you-go the medication is cheaper and a provider visit is billed separately every three months. On the membership the medication costs more and the visits are folded in. Which is cheaper depends on the dose, and the page gives a reader everything needed to work it out.
We have recorded the visit as a fee row that does not cover medication, so nothing on this site can total it as if it were a drug price. Eleven of the one hundred and fifty-eight sellers here publish a figure that is not the medication.
A count, not a list
The weight-loss section states that the service is available in forty states. It does not say which forty. Elsewhere on the same page, hormone therapy is available in six named states and peptide therapy in select states, so the site can name states when it wants to.
A count is not a list, and we have recorded no service area on that basis. One hundred and fifteen of the one hundred and fifty-eight sellers here publish no service area at all; this one publishes a number instead, which is closer but still not something a reader can check against their own address.
The city pages and the phone number mark the practice as Oklahoma-based, and its in-office services are local.
What it says about the medication
The pricing page states plainly that compounded semaglutide and tirzepatide are not FDA approved. That sentence sits directly beneath the ladders rather than in a policy document, which is the right place for it.
The prescriber is described as a licensed nurse practitioner rather than named, and the pharmacies as reputable partners rather than named. One hundred and twenty-six of the one hundred and fifty-eight sellers here name no compounding pharmacy.
No legal entity appears anywhere. The privacy policy runs to about a thousand characters and carries no company name, and no other legal page is linked from the homepage.
NP2GO's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $150/molowest step of the pay-as-you-go ladder, which continues 0.4-0.5 mg $175, 0.88-1 mg $235, 1.5-1.7 mg $250 and 2.1-2.5 mg $350; a provider visit is billed separately every three months on this lane | September 2026source |
| Semaglutide (compounded) | $199/mothe membership lane, which the seller says carries no visit fees; the same lane is $299 a month from 1.5 mg upward | September 2026source |
| Tirzepatide (compounded) | $250/molowest step of the pay-as-you-go ladder, which continues 4.4-5 mg $300, 6.6-7.5 mg $375, 8.8-10 mg $475, 11-12.5 mg $550 and 13.2-15 mg $600 | September 2026source |
| Tirzepatide (compounded) | $299/mothe membership lane, flat from 2.2 mg to 7.5 mg and $399 a month from 8.8 mg upward | September 2026source |
| Glp-1 (compounded) | $99a provider visit billed every three months on the pay-as-you-go lane; this is a fee, not a medication price, and nothing on this site may total it as one | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 158 providers reviewed here are paid partners today; the other 154 are not. See how this works.
See NP2GO's current price →Good fit if
- Buyers comparing a per-visit fee structure against a membership that folds the visits in, with both published.
- People in and around Oklahoma who want an in-person option alongside a virtual one.
- Readers who want every dose step priced before committing.
Look elsewhere if
- Anyone who needs to confirm their own state; the seller publishes a count and not a list.
- Readers who want to know which company they are contracting with.
- Buyers who want the pharmacy or the individual prescriber named.
- People who want one clear price rather than two structures to choose between.
How this review was verified
- Read the pricing page, the weight-loss programme page and the privacy policy on 6 September 2026, with a nonsense-path control on the host in the same run that returned a not-found status with about a thousand characters of shell text.
- Recorded the state figure as a count and not as a list, and left the state field empty rather than inventing one.
- Stored the quarterly provider visit as a fee row that does not cover medication, so no total on this site can add it to a drug price.
- Read the privacy policy in full and searched it for any company suffix; none appears.
- Screened the operating entity and the brand name against FDA's live warning-letter datatable, carrying a known letter as a positive control and a nonsense string as a negative control in the same pass; the positive control returned its letter and the negative returned nothing. Neither the entity nor the brand returned one. Untitled letters are published separately and were not searched, so the supportable claim is that no warning letter was found.